Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia ; volume:78 ; number:18 ; day:12 ; month:12 ; year:2018 ; pages:1911 ; date:12.2018
Drugs ; 78, Heft 18 (12.12.2018), 1911, 12.2018
- Urheber
-
Blair, Hannah A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-018-1034-z
- URN
-
urn:nbn:de:101:1-2019013120283425921059
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blair, Hannah A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
Identification of CDX2 targets in acute myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
P20. Lack of T cell exhaustion in acute myeloid leukaemia
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
Identification of CDX2 targets in acute myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
P20. Lack of T cell exhaustion in acute myeloid leukaemia
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
Identification of CDX2 targets in acute myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia